Encompass Health Corp (EHC)

Encompass Health (NYSE: EHC) has filed an automatic shelf registration statement on Form S-3, providing flexibility to offer various securities like common stock, preferred stock, warrants, and debt securities for general corporate purposes. The company, a leading operator of inpatient rehabilitation hospitals, reported $2.065.1 million in net operating revenues and $229.1 million in net income for the first half of 2026. This filing allows for future capital raising without immediately specifying amounts or prices, with potential uses including debt repayment, share repurchases, and acquisitions.

Encompass Health CEO Mark J. Tarr sold 173,148 shares of common stock for $21.7 million on August 10, 2026, yet still retains a significant stake worth over $33.69 million, signaling continued confidence in the company despite the sale. The company, a leader in post-acute healthcare with a $12.5 billion market capitalization, recently reported a 10% revenue increase and raised its full-year guidance, reflecting strong growth and market confidence. Analyst ratings remain positive with increased price targets, further reinforcing the company's optimistic outlook.

John Patrick Darby, EVP and General Counsel of Encompass Health, sold 8,906 shares for $1.1 million, reducing his direct holdings to 75,041 shares. Despite this insider selling, which could suggest a decline in confidence, the company reported strong financial performance with $12.5 billion market capitalization and $6.2 billion in revenues. Encompass Health is also expected to benefit from a 2.3% increase in Medicare payments starting October, supporting long-term growth.

Encompass Health's CFO, Douglas E. Coltharp, sold 18,869 shares for $2.4 million on August 10, a modest reduction that still leaves him with significant indirect holdings, reflecting ongoing confidence in the company. The company is demonstrating strong market performance with a $12.5 billion market cap, $6.2 billion in trailing twelve-month revenues, and raised full-year guidance for the second time this year. Analysts forecast the stock price to rise, with Truist and Raymond James maintaining "Buy" and "Strong Buy" ratings, respectively, and increasing their price targets due to strong Q2 performance and positive industry dynamics.

T. Rowe Price Associates has filed a Schedule 13G, disclosing a 5.1% beneficial ownership stake in Encompass Health Corp (EHC), totaling 5,056,225 common stock shares. The filing indicates that T. Rowe Price Associates holds sole voting power over 4,897,333 shares and sole dispositive power over all 5,056,225 shares. Importantly, the firm explicitly denies beneficial ownership of these securities, stating the filing should not be construed as an admission.